tailieunhanh - Báo cáo y học: "The devil’s in the details"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: The devil’s in the details. | Petsko Genome Biology 2010 11 117 http 2010 11 4 117 Genome Biology COMMENT L__ The devil s in the details Gregory A Petsko The Health Care Reform Bill that was recently passed by the US Congress and signed into law by President Obama has admirably simple goals to provide health care benefits to some 30 million Americans who currently have none and to begin to control the spiraling cost of health care which is threatening to make a shambles of the US economy. But as my mother was fond of saying the devil s in the details and at 2 562 pages of almost unreadable prose there are a lot of details for the devil to hide in. This shouldn t detract from the extraordinary achievement of President Obama and the Democratic Party leadership in Congress by simply getting the bill passed they accomplished something that presidents since Theodore Roosevelt have failed to do. Still there is one particular detail that is worth scientists in general - and maybe genome biologists in particular - paying some attention to. It goes by the rather unglamorous name of SA 2688 and it s an amendment to the bill. It was inserted into the final package by Pennsylvania Senator Arlen Specter a longtime champion of biomedical research and increased funding for the US National Institutes of Health NIH . The amendment is 8 pages long so I can t quote it in detail but here s a summary of what it says. The amendment creates a program called the Cures Acceleration Network CAN within the Office of the NIH Director with a 24-member oversight board . CAN is to award grants and contracts to eligible entities. to accelerate the development of high need cures including through the development of medical products and behavioral therapies . A high need cure is defined as a product that is a priority to diagnose mitigate prevent or treat harm from any disease or condition and for which the incentives of the commercial market are unlikely to result in its adequate or timely development .